Acrivon Therapeutics, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $66,700,999.
Profit Margin
| 2020 | 0 | -5.30M | |
|---|---|---|---|
| 2021 | 0 | -16.24M | |
| 2022 | 0 | -29.67M | |
| 2023 | 0 | -60.38M |
ACRV Income Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 0 | 0 | 0 | 0 |
Cost of revenue | 536K | 1.09M | 832K | 13K |
Gross profit | -536K | -1.09M | -832K | -13K |
Operating exp. | ||||
Research and development | 45.48M | 23.94M | 13.71M | 1.87M |
Selling and marketing | 134K | 0 | 0 | 0 |
Total operating expenses | 66.70M | 32.65M | 16.18M | 3.16M |
Operating income | -67.23M | -32.65M | -16.18M | -3.16M |
Other income (expenses), net | 6.84M | 1.49M | -59K | -2.13M |
Income before tax | -60.38M | -31.16M | -16.24M | -5.30M |
Income tax expense | 0 | -1.49M | 0 | -193.29K |
Net income | -60.38M | -29.67M | -16.24M | -5.30M |
Earnings per share | ||||
Basic EPS | -2.74 | -1.35 | -0.78 | -0.25 |
Diluted EPS | -2.74 | -1.35 | -0.78 | -0.25 |
| Data source | Data source |